MRI-Based Prostate Cancer Screening in an Era of MCEDs
Mark Emberton, MD, FRCS, discusses magnetic resonance imaging (MRI)-based prostate cancer screening in an era of multi-cancer early detection tests (MCEDs). Prof. Emberton explains that, while screening is beneficial, prostate cancer doesn’t lend itself to the MCED approach.
Prof. Emberton addresses high-quality imaging tools available for prostate cancer screening, mpMRI, and bi-parametric MRI. He outlines and illustrates possible approaches before enumerating challenges of previous screening trials, including poor adherence and contamination.
To combat these challenges, Prof. Emberton proposes a Zelen or embedded cohort design, calling it nondisruptive and fair, eliminating contamination, mitigating nonadherence, and permitting adjustments for underrepresented groups. Dr. Emberton summarizes that the demand for accurate prostate cancer screening and early detection is high.
Read More